Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics

References

• Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P, et al. Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population based study. J Neurol Sci. 2006;250:45–9.
   PubMed Web of Science ®Google Scholar
• Cellura E, Spataro R, Taiello AC, La Bella V. Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin Neurol Neurosurg. 2012;114:550–4.
   PubMed Web of Science ®Google Scholar
• Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol. 2012;8:22–33.
   PubMed Web of Science ®Google Scholar
• Johnson CH, Gonzalez FJ. Challenges and opportunities of metabolomics. J Cell Physiol. 2012;227:2975–81.
   PubMed Web of Science ®Google Scholar
• Zhang A, Sun H, Wang P, Han Y, Wang X. Recent and potential developments of biofluid analyses in metabolomics. J Proteomics. 2012;75:1079–88.
   PubMed Web of Science ®Google Scholar
• Eckhart AD, Beebe K, Milburn M. Metabolomics as a key integrator for ‘omic’ advancement of personalized medicine and future therapies. Clin Transl Sci. 2012;5:285–8.
   PubMed Web of Science ®Google Scholar
• Milburn MV, Lawton KA, McDunn JE, Ryals JA, Guo L. Understanding Cancer Metabolism Through Global Metabolomics. In: Suhre K, editor. Genetics Meets Metabolomics: from Experiment to Systems Biology: Springer; 2012. pp. 177–90.
   Google Scholar
• Lawton KA, Cudkowicz ME, Brown MV, Alexander D, Caffrey R, Wulff JE, et al. Biochemical alterations associated with ALS. Amyotroph Lateral Scler. 2012;13:110–8.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler. 2012;13:1–10.
   PubMed Web of Science ®Google Scholar
• Members MSIB, Sansone SA, Fan T, Goodacre R, Griffin JL, Hardy NW, et al. The metabolomics standards initiative. Nature Biotechnology. 2007;25:846–8.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, non-targeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem. 2009;81:6656–67.
   PubMed Web of Science ®Google Scholar
• Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, et al. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol. 2009;37:521–35.
   PubMed Web of Science ®Google Scholar
• Ward JH Jr. Hierarchical Grouping to Optimize an Objective Function. Journal of the American Statistical Association. 1963;48:236–44.
   Web of Science ®Google Scholar
• Breiman L. Random Forests. In: Schapire RE, editor. Machine Learning. 45: Kluwer Academic Publishers; 2001. pp. 5–32.
   Google Scholar
• Cortes C, Vapnik V. Support-vector networks. Machine Learning.20 (1995).p. 273–97.
   Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B. 1995;57: 289–300.
   Web of Science ®Google Scholar
• Ganesalingam J, An J, Bowser R, Andersen PM, Shaw CE. pNfH is a promising biomarker for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:146–9.
   PubMed Web of Science ®Google Scholar
• von Neuhoff N, Oumeraci T, Wolf T, Kollewe K, Bewerunge P, Neumann B, et al. Monitoring CSF Proteome Alterations in Amyotrophic Lateral Sclerosis: Obstacles and Perspectives in Translating a Novel Marker Panel to the Clinic. PLoS One. 2012;7:e44401.
   PubMed Web of Science ®Google Scholar
• Verstraete E, Kuiperij HB, van Blitterswijk MM, Veldink JH, Schelhaas HJ, van den Berg LH, et al. TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13:446–51.
   PubMed Web of Science ®Google Scholar
• Tortelli R, Ruggieri M, Cortese R, D’Errico E, Capozzo R, Leo A, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol. 2012;19:1561–7.
   PubMed Web of Science ®Google Scholar
• Nardo G, Pozzi S, Pignataro M, Lauranzano E, Spano G, Garbelli S, et al. Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One. 2011;6:e25545.
   PubMed Web of Science ®Google Scholar
• Wilson ME, Boumaza I, Lacomis D, Bowser R. Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis. PLoS One. 2010;5:e15133.
   PubMed Web of Science ®Google Scholar
• Noto Y, Shibuya K, Sato Y, Kanai K, Misawa S, Sawai S, et al. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. Amyotroph Lateral Scler. 2011;12:140–3.
   PubMed Web of Science ®Google Scholar
• Ryberg H, An J, Darko S, Lustgarten JL, Jaffa M, Gopalakrishnan V, et al. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve. 2010 ;42:104–11.
   PubMed Web of Science ®Google Scholar
• Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, Simmons Z, et al. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology. 2009;72:14–9.
   PubMed Web of Science ®Google Scholar
• Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X, et al. Identification of potential CSF biomarkers in ALS. Neurology. 2006;66:1218–22.
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, et al. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem. 2005;95:1461–71.
   PubMed Web of Science ®Google Scholar
• Lilo E, Wald-Altman S, Solmesky LJ, Ben Yaakov K, Gershoni-Emek N, Bulvik S, et al. Characterization of human sporadic ALS biomarkers in the familial ALS transgenic mSOD1-G93A mouse model. Hum Mol Genet. 2013;
   PubMed Web of Science ®Google Scholar
• Figueroa-Romero C, Hur J, Bender DE, Delaney CE, Cataldo MD, Smith AL, et al. Identification of epigenetically altered genes in sporadic amyotrophic lateral sclerosis. PLoS One. 2012;7:e52672.
   PubMed Web of Science ®Google Scholar
• Blasco H, Corcia P, Pradat PF, Bocca C, Gordon PH, Veyrat-Durebex C, et al. Metabolomics in Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis: An Untargeted Approach via High-Resolution Mass Spectrometry. J Proteome Res. 2013;12:3746–54.
   PubMed Web of Science ®Google Scholar
• Kruger T, Lautenschlager J, Grosskreutz J, Rhode H. Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery. Proteomics Clin Appl. 2013; 7:123–35.
   PubMed Web of Science ®Google Scholar
• Funalot B, Desport JC, Sturtz F, Camu W, Couratier P. High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10:113–7.
   PubMed Web of Science ®Google Scholar
• Desport JC, Preux PM, Magy L, Boirie Y, Vallat JM, Beaufrere B, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr. 2001;74:328–34.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Oudart H, Rene F, Gonzalez de Aguilar JL, Loeffler JP. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci U S A. 2004;101:11159–64.
   PubMed Web of Science ®Google Scholar
• Dorst J, Kuhnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011; 258:613–7.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar JL, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008 ;70:1004–9.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75–82.
   PubMed Web of Science ®Google Scholar
• Dupuis L, Gonzalez de Aguilar JL, Echaniz-Laguna A, Eschbach J, Rene F, Oudart H, et al. Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons. PLoS One. 2009; 4:e5390.
   PubMed Web of Science ®Google Scholar
• Hervias I, Beal MF, Manfredi G. Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve. 2006;33: 598–608.
   PubMed Web of Science ®Google Scholar
• Li Q, Vande Velde C, Israelson A, Xie J, Bailey AO, Dong MQ, et al. ALS-linked mutant superoxide dismutase-1 (SOD1) alters mitochondrial protein composition and decreases protein import. Proc Natl Acad Sci U S A. 2010; 107:21146–51.
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62.
   PubMed Web of Science ®Google Scholar
• Mattson MP, Liu D. Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. Neuromolecular Med. 2002;2:215–31.
   PubMed Web of Science ®Google Scholar
• Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000 ;80:1107–213.
   PubMed Web of Science ®Google Scholar
• Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002;52:448–57.
   PubMed Web of Science ®Google Scholar
• Jana A, Hogan EL, Pahan K. Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death. J Neurol Sci. 2009;278:5–15.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between Disease Progression and Serum Levels of Lipid, Urate, Creatinine and Ferritin in Japanese Patients with Amyotrophic Lateral Sclerosis: A Cross-Sectional Study. Intern Med. 2012;51:1501–8.
   PubMed Web of Science ®Google Scholar
• Keizman D, Ish-Shalom M, Berliner S, Maimon N, Vered Y, Artamonov I, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress?J Neurol Sci. 2009;285:95–9.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Zhang M, Quiroz Zarate A, Jaffa M, Yu H, Cudkowicz ME, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012;259:1923–8.
   PubMed Web of Science ®Google Scholar
• Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:37–44.
   PubMed Web of Science ®Google Scholar